Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Capecitabine Metronomic Chemotherapy Versus Conventional Chemotherapy as Maintenance Treatment in Metastatic Colorectal Cancer

NCT02893540 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT02893540
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02893540 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Capecitabine Metronomic Chemotherapy Versus Conventional Chemotherapy as Maintenance Treatment in Metastatic Colorectal Cancer
Lead sponsor
Ruijin Hospital
Phase
Phase 2/3
Overall status
Unknown status
Start date
September 30, 2016
Completion date
August 31, 2019
Enrollment
250 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer